Regeneron high-dose Eylea gains FDA approval (NASDAQ:REGN)


FDA APPROVED text on sticker on the blue background with pen and keyboard

Iryna Drozd

The US FDA has approved Regeneron Pharmaceuticals’ (NASDAQ:REGN) high-dose (“HD”) version of its blockbuster therapy Eylea (aflibercept).

The new formulation allows patients to receive treatment less frequently. HD Eylea is dosed every 4 weeks for the first 3 months, every 8 to

Source link

Leave A Reply

Your email address will not be published.